|Treatments:||Chemotherapy, Radiation||Hospital:||University of Heidelberg|
Patients: This study involved 25 patients with recurrent or progressive gliomas. Glioblastoma was the most common form, in 32% of the patients. Other patients had oligoastrocytoma, oligodendroglioma, and astrocytoma. The median age was 39, ranging from 6 to 61 years old. There were 14 females and 11 males.
Treatment: Patients were treated with radiation and chemotherapy. The radiation therapy used was high-precision fractionated stereotactic radiotherapy, and the chemotherapy drug was temozolomide.
Toxicity: Minor toxicities included alopecia, headaches, nausea, and vomiting.
Results: The median overall survival from the time the patients were initially diagnosed was 59 months, ranging from 15 to 192. The median overall survival from the time the patients received the radiation treatment in this study was 8 months, ranging from 3 to 14 months.
Support: Researchers involved in this study received funds from Schering-Plough, which markets temozolomide as Temodar“.
Correspondence: Dr. Stephanie E. Combs